Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Allergol Immunopathol (Madr). 2022 May 1;50(3):24-37. doi: 10.15586/aei.v50i3.507. eCollection 2022.
The purpose of this meta-analysis is to systematically evaluate the efficacy of probiotics on allergic rhinitis (AR).
Collecting randomized controlled trials (RCTs) with probiotics as intervention measures for AR, two researchers independently screened the literature, extracted the data and evaluated the methodological quality of the included studies, and used RevMan 5.3 software for meta-analysis to observe the effects of probiotics on Rhinitis Quality of Life (RQLQ) scores, Rhinitis Total Symptom Scores (RTSS), blood eosinophil count, total and antigen-specific serum immunoglobulin E (IgE) levels by using the fixed- or the random-effects model to calculate the pooled risk for significant heterogeneity.
A total of 2708 patients were included in 30 RCTs. Meta-analysis results showed that the RQLQ global scores (mean difference [MD] = -9.43; P < 0.00001), RQLQ nasal scores (MD = -1.52; P = 0.03), and RTSS nasal scores (MD = -1.96; P = 0.02) significantly improved in the probiotic group when compared with those in the placebo group. There was no significant difference in blood eosinophil count (MD = -0.09; P=0.82), RQLQ eye scores (MD = -1.45; P = 0.07), RTSS global scores (MD = -2.24; P = 0.26), RTSS eye scores (MD = -0.39; P = 0.31), total and antigen-specific serum IgE levels (MD = -0.04; P = 0.7 and MD = -0.08; P = 0.81) between the probiotic and the placebo group.
Compared with the placebo group, the quality of life and symptoms of patients with AR significantly improved in the probiotic group, thus providing a new potential method for the application of probiotics in AR. However, because of the limited evidence for the current study outcomes, the heterogeneity of research, and the differences in research results, more high-quality studies are needed to in the future.
本荟萃分析旨在系统评估益生菌对过敏性鼻炎（AR）的疗效。
收集益生菌作为 AR 干预措施的随机对照试验（RCT），两名研究人员独立筛选文献、提取数据并评价纳入研究的方法学质量，使用 RevMan 5.3 软件进行荟萃分析，观察益生菌对鼻炎生活质量（RQLQ）评分、鼻炎总症状评分（RTSS）、血嗜酸性粒细胞计数、总和抗原特异性血清免疫球蛋白 E（IgE）水平的影响，采用固定或随机效应模型计算显著异质性的汇总风险比。
共纳入 30 项 RCT 的 2708 例患者。Meta 分析结果显示，益生菌组的 RQLQ 总体评分（均数差 [MD] = -9.43；P < 0.00001）、RQLQ 鼻部评分（MD = -1.52；P = 0.03）和 RTSS 鼻部评分（MD = -1.96；P = 0.02）明显优于安慰剂组。益生菌组与安慰剂组之间的血嗜酸性粒细胞计数（MD = -0.09；P=0.82）、RQLQ 眼部评分（MD = -1.45；P = 0.07）、RTSS 总体评分（MD = -2.24；P = 0.26）、RTSS 眼部评分（MD = -0.39；P = 0.31）、总和抗原特异性血清 IgE 水平（MD = -0.04；P = 0.7 和 MD = -0.08；P = 0.81）差异均无统计学意义。
与安慰剂组相比，益生菌组患者的生活质量和症状明显改善，为益生菌在 AR 中的应用提供了一种新的潜在方法。然而，由于本研究结果的证据有限、研究的异质性以及研究结果的差异，未来需要更多高质量的研究。
